Our Pricing

Weight Loss On Wegovy Maintenance Dose: What Clinical Evidence Shows

Many UK patients wonder about weight loss on wegovy maintenance dose after completing the initial titration schedule. Clinical trial data demonstrates that patients typically continue to lose weight during the maintenance phase at 2.4mg, with the STEP 1 trial showing sustained reductions averaging 14.9% of initial body weight at 68 weeks. At Cured Pharmacy, our UK-registered clinical team helps patients understand realistic expectations for long-term Wegovy treatment, with transparent pricing from £79.00 and ongoing prescriber support throughout your weight management journey.

Clinical Evidence for Weight Loss On Wegovy Maintenance Dose

The STEP clinical trial programme provides robust evidence that weight loss on wegovy maintenance dose continues well beyond the initial titration period. In STEP 1, participants who reached the 2.4mg maintenance dose experienced progressive weight reduction through week 68, with mean weight loss of 14.9% from baseline [1]. Critically, the trial data shows that maximum weight loss typically occurred between weeks 60-68, not immediately upon reaching maintenance dosing.

This delayed peak effect reflects semaglutide's mechanism of action as a GLP-1 receptor agonist. The medication continues to suppress appetite, slow gastric emptying, and regulate glucose-dependent insulin secretion even after dose escalation stops [2]. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) frequently advises patients that the maintenance phase represents a therapeutic plateau where the medication works at optimal efficacy, not a ceiling where benefits stop.

Real-world UK prescribing data aligns with trial findings. Patients who maintain adherence to the 2.4mg weekly injection, combined with lifestyle modifications, typically see continued gradual weight reduction for 12-18 months before reaching a stable weight [1]. Individual responses vary based on baseline metabolic health, dietary adherence, and physical activity levels.

How Long Does Weight Loss Continue at 2.4mg Wegovy Maintenance

The trajectory of weight loss on wegovy maintenance dose follows a predictable pattern in clinical studies. Most patients experience the steepest weight reduction during weeks 0-20 (titration phase), followed by continued but slower loss during weeks 20-68 on the 2.4mg dose [1]. The STEP 1 extension study tracked participants beyond the initial 68 weeks, demonstrating weight stability rather than regain when treatment continued.

Weight loss velocity typically slows after 6-9 months at maintenance dosing, but this doesn't indicate treatment failure. The medication continues to provide appetite suppression and metabolic benefits that prevent weight regain — a critical distinction from diet-only approaches where most patients experience rebound weight gain [3]. UK prescribers assess ongoing treatment benefit based on sustained weight loss of at least 5% from baseline, maintained quality of life improvements, and absence of problematic adverse effects.

Factors Influencing Maintenance Phase Weight Loss

Individual response to wegovy maintenance dose varies significantly. Patients with higher baseline BMI often experience greater absolute weight loss, though percentage reductions remain comparable across weight categories [1]. Adherence to the weekly injection schedule proves critical — missed doses can disrupt the steady-state semaglutide levels required for consistent appetite suppression. Concurrent lifestyle modifications, particularly protein intake optimisation and resistance training, help preserve lean muscle mass during weight loss and may extend the duration of continued reduction at maintenance dosing.

What Happens If Weight Loss Plateaus on Wegovy Maintenance Dose

A weight plateau during maintenance dosing doesn't necessarily indicate treatment failure. The STEP trials defined treatment response as sustained weight loss of ≥5% from baseline, which 86.4% of participants achieved at the 2.4mg dose [1]. If weight stabilises after achieving clinically meaningful reduction, this represents successful weight maintenance — an outcome most diet-only interventions fail to deliver long-term.

UK prescribers may reassess treatment strategy if weight loss plateaus before reaching therapeutic targets. Options include reviewing dietary patterns for unrecognised caloric intake, screening for medications that promote weight gain, evaluating thyroid function, or considering whether the patient has reached their biological set point. Some patients may benefit from structured dietitian support or adjustments to physical activity, though dose escalation beyond 2.4mg isn't licensed in the UK for Wegovy.

The STEP 4 withdrawal study provides compelling evidence for Wegovy's role in weight maintenance. Participants who discontinued semaglutide after reaching maintenance dose regained approximately two-thirds of their lost weight within 48 weeks, while those continuing treatment maintained their reduction [4]. This underscores that Wegovy addresses chronic weight regulation, not just initial weight loss.

When to Consult Your UK Prescriber

Contact your prescriber if you experience weight regain of >3% while adherent to maintenance dosing, as this may indicate inadequate therapeutic response or underlying metabolic changes requiring investigation. Similarly, seek clinical review if you develop persistent gastrointestinal side effects that weren't present during titration, as these may affect nutritional intake and treatment sustainability. At Cured Pharmacy, our UK clinical team provides ongoing monitoring throughout your Wegovy treatment, with prescriber access included in your treatment package.

Wegovy Maintenance Dose vs Other Weight Loss Treatments

When comparing weight loss on wegovy maintenance dose to alternative treatments, semaglutide demonstrates superior efficacy in head-to-head trials. The STEP 8 study directly compared Wegovy 2.4mg to liraglutide 3mg (Saxenda), showing mean weight loss of 15.8% vs 6.4% respectively at 68 weeks [5]. This substantial difference reflects semaglutide's longer half-life (approximately 7 days vs 13 hours), allowing once-weekly dosing and more stable receptor activation.

Tirzepatide (Mounjaro), a dual GIP/GLP-1 receptor agonist, shows even greater weight reduction in trials, with the SURMOUNT-1 study reporting up to 22.5% mean weight loss at the highest dose [6]. However, tirzepatide isn't currently licensed for weight management in the UK outside diabetes treatment, though this may change pending MHRA review. For UK patients, Wegovy remains the most established injectable weight loss medication with extensive real-world safety data.

Managing Expectations During Wegovy Maintenance Phase

Realistic expectations prove essential for treatment satisfaction during the maintenance phase. While clinical trials show impressive average results, individual responses vary considerably. Approximately 13.6% of STEP 1 participants didn't achieve the 5% weight loss threshold at maintenance dosing [1], highlighting that Wegovy isn't universally effective. Genetic factors, medication interactions, sleep quality, stress levels, and gut microbiome composition all influence treatment response.

UK prescribers emphasise that Wegovy addresses one component of weight regulation — appetite and satiety signalling — but doesn't override all physiological weight defence mechanisms. Patients who combine maintenance dosing with structured nutrition plans, regular physical activity (particularly resistance training), adequate sleep, and stress management typically achieve superior outcomes compared to medication alone. The STEP trials included lifestyle counselling alongside semaglutide, so trial results reflect combined intervention effects.

Weight loss velocity naturally slows as patients approach healthier body weights. This reflects adaptive thermogenesis, where metabolic rate decreases in response to weight loss [3]. Patients shouldn't expect the same rate of reduction in months 12-18 as they experienced during initial titration. Stable weight at a significantly reduced level represents treatment success, not failure.

Long-Term Treatment Considerations

Current evidence suggests Wegovy works as a long-term weight management medication rather than a short-term intervention. The STEP 4 withdrawal data demonstrates significant weight regain upon discontinuation [4], indicating most patients require ongoing treatment to maintain reductions. UK prescribers assess continuation based on sustained clinical benefit, tolerability, and patient preference. At Cured Pharmacy, we provide transparent ongoing pricing from £79.00 per month, with no hidden fees or mandatory long-term commitments, allowing patients to make informed decisions about treatment duration.

Starting Wegovy Treatment at Cured Pharmacy

If you're considering Wegovy for weight management, Cured Pharmacy offers a streamlined pathway to treatment. Our free online consultation takes under 3 minutes and is reviewed by UK-registered prescribers who assess your suitability based on NICE guidelines and MHRA licensing criteria. Wegovy is licensed for adults with BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities such as hypertension, type 2 diabetes, or dyslipidaemia.

We supply only genuine UK-licensed Wegovy pens, sourced through regulated pharmaceutical wholesalers and stored in our GPhC-registered pharmacy (9012511). Each prescription includes the complete titration schedule from 0.25mg through to 2.4mg maintenance dosing, with clear injection technique guidance and ongoing prescriber support. Discreet packaging ensures complete privacy, with delivery direct to your UK address.

Pricing remains transparent from your first visit — £79.00 per month for Wegovy treatment, with the exact cost confirmed before you complete your clinical assessment. Unlike some providers, we don't add consultation fees, prescription charges, or delivery costs after you've started the process. Our lowest price guarantee means you're getting competitive UK pricing for genuine licensed medication, dispensed by qualified pharmacy professionals under the supervision of our superintendent pharmacist Tarun Kumar.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
3. Rosenbaum, M., & Leibel, R. L. (2010). Adaptive thermogenesis in humans. International Journal of Obesity, 34(S1), S47–S55. https://doi.org/10.1038/ijo.2010.184
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
5. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., & STEP 8 Investigators. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619
6. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and clinical trial outcomes do not guarantee specific weight loss for any patient.